World Health Organization. Weekly Epidemiological Record. Geneva, Switzerland: World Health Organization; 1997:341-348.
Alter MJ, Kruszon-Moran D, Nainan OV.
et al. The prevalence of hepatitis C virus infection in the United States,
1988 through 1994. N Engl J Med.1999;341:556-562.
Alter MJ, Margolis HS, Krawczynski K.
et al. The natural history of community acquired hepatitis C in the United
States. N Engl J Med.1992;327:1899-1905.
Villano SA, Vlahov D, Nelson KE, Cohn S, Thomas DL. Persistence of viremia and the importance of long-term follow-up after
acute hepatitis C infection. Hepatology.1999;29:908-914.
Farci P, Alter HJ, Wong D.
et al. A long-term study of hepatitis C virus replication in non-A, non-B
hepatitis. N Engl J Med.1991;325:98-104.
Barrera JM, Bruguera M, Ercilla MG.
et al. Persistent hepatitis C viremia after acute self-limiting posttransfusion
hepatitis C. Hepatology.1995;21:639-644.
Mattsson L, Sonnerborg A, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up
study of hepatitis C virus markers. Liver.1993;13:274-278.
Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical outcomes after transfusion-associated hepatitis C. N Engl J Med.1995;332:1463-1466.
Seeff LB, Buskell-Bales ZB, Wright EC.
et al. Long-term mortality after transfusion-associated non-A, non-B hepatitis. N Engl J Med.1992;327:1906-1911.
Koretz RL, Abbey H, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis: looking back in the second
decade. Ann Intern Med.1993;119:110-115.
Kenny-Walsh E. Clinical outcomes after hepatitis C infection from contaminated anti-D
immune globulin. N Engl J Med.1999;340:1228-1233.
Kiyosawa K, Sodeyama T, Tanaka E.
et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and
hepatocellular carcinoma: analysis by detection of antibody to hepatitis C
Hopf U, Moller B, Kuther D.
et al. Long-term follow-up of posttransfusion and sporadic chronic hepatitis
non-A, non-B and frequency of circulating antibodies to hepatitis C virus
(HCV). J Hepatol.1990;10:69-76.
Di Bisceglie AM, Goodman ZD, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic posttransfusion
Tremolada F, Casarin C, Alberti A.
et al. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol.1992;16:273-281.
Seeff LB, Miller RN, Rabkin CS.
et al. 45-year follow-up of hepatitis C virus infection in healthy young adults. Ann Intern Med.2000;132:105-111.
Vogt M, Lang T, Frosner G.
et al. Prevalence and clinical outcome of hepatitis C infection in children
who underwent cardiac surgery before the implementation of blood-donor screening. N Engl J Med.1999;341:866-870.
Corrao G, Aricò S. Independent and combined action of hepatitis C virus infection and
alcohol consumption on the risk of symptomatic liver cirrhosis. Hepatology.1998;27:914-919.
Ostapowicz G, Watson KJR, Locarnini SA, Desmond PV. Role of alcohol in the progression of liver disease caused by hepatitis
C virus infection. Hepatology.1998;27:1730-1735.
Pessione F, Degos F, Marcellin P.
et al. Effect of alcohol consumption on serum hepatitis C virus RNA and histological
lesions in chronic hepatitis C. Hepatology.1998;27:1717-1722.
Vlahov D, Graham N, Hoover D.
et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected
injection drug users: plasma viral load and CD4+ cell count. JAMA.1998;279:35-40.
Hoofnagle JH, Dusheiko GM, Seeff LB, Jones A, Waggoner JG, Bales ZB. Seroconversion from hepatitis B e antigen to antibody in chronic type
B hepatitis. Ann Intern Med.1981;94:744-748.
Mellors JW, Rinaldo CRJ, Gupta P.
et al. Prognosis in HIV-1 infection predicted by the quantity of virus in
Gretch D, Corey L, Wilson J.
et al. Assessment of hepatitis C virus RNA levels by quantitative competitive
RNA polymerase chain reaction: high titer viremia correlates with advanced
stage of disease. J Infect Dis.1994;169:1219-1225.
De Moliner L, Pontisso P, De Salvo GL, Cavalletto L, Chemello L, Alberti A. Serum and liver HCV RNA levels in patients with chronic hepatitis C:
correlation with clinical and histological features. Gut.1998;42:856-860.
Haydon GH, Jarvis LM, Blair CS.
et al. Clinical significance of intrahepatic hepatitis C virus levels in patients
with chronic HCV infection. Gut.1998;42:570-575.
Negro F, Krawczynski K, Quadri R.
et al. Detection of genomic- and minus-strand of hepatitis C virus RNA in
the liver of chronic hepatitis C patients by strand-specific semiquantitative
reverse transcriptase polymerase chain reaction. Hepatology.1999;29:536-542.
Vlahov D, Anthony JC, Muñoz A.
et al. The ALIVE Study: a longitudinal study of HIV-1 infection in intravenous
drug users: description of methods. J Drug Issues.1991;21:759-776.
Villano SA, Vlahov D, Nelson KE, Lyles CM, Cohn S, Thomas DL. Incidence and risk factors for hepatitis C among injection drug users
in Baltimore, Maryland. J Clin Microbiol.1997;35:3274-3277.
Lau JY, Davis GL, Kniffen J.
et al. Significance of serum hepatitis C virus RNA levels in chronic hepatitis
McOmish F, Yap PL, Dow BC.
et al. Geographical distribution of hepatitis C virus genotypes in blood donors:
an international collaborative survey. J Clin Microbiol.1994;32:884-892.
Levine OS, Vlahov D, Koehler J, Cohn S, Spronk AM, Nelson KE. Seroepidemiology of hepatitis B virus in a population of injecting
drug users: association with drug injection patterns. Am J Epidemiol.1995;142:331-341.
Inglesby TV, Rai R, Astemborski J.
et al. A prospective, community-based evaluation of liver enzymes in individuals
with hepatitis C after drug use. Hepatology.1999;29:590-596.
Knodell RG, Ishak KG, Black WC.
et al. Formulation and application of a numerical scoring system for assessing
histological activity in asymptomatic chronic active hepatitis. Hepatology.1981;1:431-435.
Thomas DL, Vlahov D, Solomon L.
et al. Correlates of hepatitis C virus infections among injection drug users
in Baltimore. Medicine.1995;74:212-220.
Garfein RS, Vlahov D, Galai N, Doherty MC, Nelson KE. Viral infections in short-term injection drug users: the prevalence
of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic
viruses. Am J Public Health.1996;86:655-661.
Thomas DL, Astemborski J, Vlahov D.
et al. Determinants of the quantity of hepatitis C virus RNA. J Infect Dis.2000;181:844-851.
Ohkawa K, Hayashi N, Yuki N.
et al. Long-term follow-up of hepatitis B virus and hepatitis C virus replicative
levels in chronic hepatitis patients coinfected with both viruses. J Med Virol.1995;46:258-264.
Sheen IS, Liaw YF, Chu CM, Pao CC. Role of hepatitis C virus infection in spontaneous hepatitis B surface
antigen clearance during chronic hepatitis B virus infection. J Infect Dis.1992;165:831-834.
Darby SC, Ewart DW, Giangrande PL.
et al. Mortality from liver cancer and liver disease in haemophilic men and
boys in UK given blood products contaminated with hepatitis C. Lancet.1997;350:1425-1431.
Eyster ME, Diamondstone LS, Lien JM, Ehmann WC, Quan S, Goedert JJ. Natural history of hepatitis C virus infection in multitransfused hemophiliacs:
effect of coinfection with human immunodeficiency virus. J Acquir Immune Defic Syndr.1993;6:602-610.
Nishiguchi S, Kuroki T, Nakatani S.
et al. Randomised trial of effects of interferon-α on incidence of hepatocellular
carcinoma in chronic active hepatitis C with cirrhosis. Lancet.1995;346:1051-1055.
Mazzella G, Accogli E, Sottili S.
et al. Alpha interferon treatment may prevent hepatocellular carcinoma in
HCV-related liver cirrhosis. J Hepatol.1996;24:141-147.
Kasahara A, Hayashi N, Mochizuki K.
et al. Risk factors for hepatocellular carcinoma and its incidence after interferon
treatment in patients with chronic hepatitis C. Hepatology.1998;27:1394-1402.